Table of Contents Table of Contents
Previous Page  98 / 916 Next Page
Show Menu
Previous Page 98 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S69–S105

ferent conditions impact on their overall well being and be active

participants. The tool will be practically demonstrated.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


The efficacy and safety of lurasidone

in adolescent patients with

schizophrenia: Results of functional

and quality of life measures from a

6-week, double-blind,

placebo-controlled study

R. Findling

1 ,

, R. Goldman


, J. Cucchiaro


, L. Deng


, A. Loebel



Johns Hopkins University and the Kennedy Krieger Institute,

Department of Psychiatry and Behavioral Sciences, Baltimore, MD,



Sunovion Pharmaceuticals Inc., Medical Affairs, Fort Lee, NJ, USA


Sunovion Pharmaceuticals Inc., Clinical Operations, Fort Lee, NJ, USA


Sunovion Pharmaceuticals Inc., Biostatistics, Fort Lee, NJ, USA


Sunovion Pharmaceuticals Inc., Clinical Development, Fort Lee, NJ,


Corresponding author.


Lurasidone, an atypical antipsychotic, demon-

strated efficacy and safety in adults with schizophrenia.


To evaluate the efficacy and safety of lurasidone

in adolescent patients with schizophrenia.


Adolescents (13–17 years old) with schizophrenia were

randomly assigned to six weeks of double-blind treatment with

lurasidone 37mg/day, 74mg/day or placebo. An ANCOVA using

an LOCF approach was performed to assess change from baseline

on secondary study endpoints: Pediatric Quality of Life Enjoyment

and Satisfaction Questionnaire (PQ-LES-Q) and Children’s Global

Assessment Scale (CGAS).


Patients were randomized to lurasidone 37mg/d



= 108), 74mg/day (


= 106), or placebo (


= 112). Placebo-

adjusted LS mean improvement at week 6 on the PQ-LES-Q was

5.3 (


= 0.001) and 5.8 (


< 0.001) for the 37mg/day and 74mg/day

groups, respectively; and, on the CGAS was 4.6 (


= 0.002) and 4.9



< 0.001) for the 37mg/day and 74mg/d groups, respectively.

The most common adverse events occurring at

5% in either

lurasidone group and at least twice the rate of placebo were:

nausea, somnolence, akathisia, vomiting and sedation. Mean

change in weight at week 6 for placebo, 37mg/day, and 74mg/day

groups was 0.05 kg, 0.17 kg, and 0.49 kg, respectively. Lurasidone

treated patients did not show clinically meaningful differences

from placebo on laboratory measures of cholesterol, triglycerides,

glucose, and prolactin.


Adolescent patients with schizophrenia treatedwith

lurasidone demonstrated significant improvement in quality of

life and function. Lurasidone was generally well-tolerated and

associated with minimal changes in weight and metabolic parame-

ters. Sponsored by Sunovion Pharmaceuticals Inc.

identifier: NCT01911429.

Disclosure of interest

Dr. Findling receives or has received

research support, acted as a consultant and/or served on a speaker’s

bureau for Alcobra, American Academy of Child & Adolescent

Psychiatry, American Physician Institute, American Psychiatric

Press, Bracket, CogCubed, Cognition Group, Coronado Biosciences,

Dana Foundation, Elsevier, Forest, Guilford Press, Ironshore, Johns

Hopkins University Press, Jubilant Clinsys, KemPharm, Lundbeck,

Merck, NIH, Neurim, Novartis, Otsuka, Oxford University Press,

Pfizer, Physicians Postgraduate Press, Purdue, Rhodes Pharma-

ceuticals, Roche, Sage, Shire, Sunovion, Supernus Pharmaceuticals,

Transcept Pharmaceuticals, Tris, Validus, and WebMD. Drs. Gold-

man, Cucchiaro, Deng, and Loebel are employees of Sunovion

Pharmaceuticals Inc.


Clinical characteristics associated

with suicide attempt in patients with

bipolar disorder

M.-E.-M. Vismara

, B. D

ell’Osso , C. Dobrea , L. Cremaschi ,

G. Benedetta , C. Arici , B. Benatti , L. Oldani , A.-C. Altamura

Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,

Department of Psychiatry-University of Milan, Milan, Italy

Corresponding author.


Bipolar disorder (BD) is a chronic, highly disabling

condition, associated with a high burden of morbidity and mor-

tality, often secondary to suicidal behaviors. In previous reports,

different variables have been associated with a higher risk of sui-

cidal acts, with variable effect.


To evaluate which socio-demographic and clinical

variables correlate with suicide attempts in bipolar patients.


To enrich literature data about suicidal behaviour in BD.


A sample of 362 BD patients (DSM IV-TR) was retro-

spectively collected and divided in two subgroups, in relation to

the presence of a previous suicide attempt. Socio-demographic

and clinical variables were compared between attempters and

non-attempters using Correctedmultivariate analysis of covariance



A total of 26,2% of analyzed patients attempted sui-

cide in their lifespan, and approximately one third of them

had multiple suicide attempts (i.e.

2; 31%). Depressive polarity

at index mood episode, higher number of psychiatric hospi-

talizations, comorbidity with alcohol abuse, eating disorders

and psychiatric poly-comorbidity were significantly associated

with suicide attempt. Additionally, treatment with lithium, poly-

pharmacotherapy (

4 current drugs) and higher recurrence of

psychosocial rehabilitation were significantly more frequent in

patients who attempted suicide.


The present paper reported a correlation with some

specific clinical variables and the lifetime presence of suicide

attempt in patients with BD. Although these retrospective findings

did not address the causality issue, theymay be of clinical relevance

in order to better understand suicidal behavior in BD and to adopt

proper strategies to prevent suicide in higher risk patients.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


What is the relationship between the

levels of work-stress and burnout?

R. Ptacek

1 ,

, J. Raboch


, M. Vnukova


, D. Dubacova



First Faculty of Medicine–Charles University, Department of

Psychiatry, Prague 2, Czech Republic


University of New York in Prague, Psychology, Prague, Czech


Corresponding author.


Burnout is constantly becoming more exhaustively

researched topic. It is assumed there is strong relationship between

burnout and work-stress. The aim of this study was to investi-

gate the relationship between burnout and work-stress in order

to test the hypothesis that there is an association between these

two variables.


The study sample comprised of economically active

Czech population, that was a representative sample. Data was

gained through combination of interviews and questionnaires